Cancer Genetics (CGIX) Tops Q3 EPS by 5c
Tweet
Share
E-mailCancer Genetics (NASDAQ: CGIX) reported Q3 EPS of ($0.23), $0.05 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $6.8 million versus the consensus estimate of $6.93 million.
For earnings history and earnings-related data on Cancer Genetics (CGIX) click here.
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
